Trial · NCT05180461
Emodepside Phase II Trial for Treatment of Onchocerciasis
NCT05180461, Phase 2, Unknown, Drugs for Neglected Diseases
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Emodepside Phase II Trial for Treatment of Onchocerciasis. Trials, record NCT05180461. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05180461
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Emodepside Phase II Trial for Treatment of Onchocerciasis
- NCT number
- NCT05180461
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 578 participants, estimated
- Lead sponsor
- Drugs for Neglected Diseases
- Conditions
- Onchocerciasis
- Interventions
- emodepside, matching placebo of emodepside, ivermectin, matching placebo of ivermectin
- First posted
- 2022-01-06
- Last updated
- 2024-03-05
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Part 1 - absence (or presence) of live female adult worms with normal embryogenesis | 12 months | Absence (or presence) of live female adult worms with normal embryogenesis, assessed by histological examination of nodules collected on nodulectomy |
| Primary | Part 1 - absence (or presence) of skin microfilariae (co-primary outcome) | 12 months | Absence (or presence) of skin microfilariae across four skin snips |
| Primary | Part 2 - absence (or presence) of skin microfilariae | 24 months | Absence (or presence) of skin microfilariae, assessed across all skin snips in a participant |
| Secondary | Part 1- absence (or presence) of live female adult worms | 12 months | The absence (or presence) of live female adult worms, assessed by histological examination of nodules collected after nodulectomy |
| Secondary | Part 1 - presence (or absence) of dead female adult worms | 12 months | The presence (or absence) of dead female adult worms, assessed by histological examination of nodules collected after nodulectomy |
| Secondary | Part 1 - Absence (or presence) of skin microfilariae | up to 12 months | Absence (or presence) of skin microfilariae |
| Secondary | Part 1 - reduction in skin microfilarial density | up to 12 months | The reduction in skin microfilarial density, defined as the mean number of microfilariae per milligram per subject, at all time-points after treatment related to baseline: change and percentage reduction |
| Secondary | Part 1 - Absence (or presence) of microfilariae in nodular tissue | 12 months | The absence (or presence) of microfilariae in nodular tissue assessed by histological examination of nodules collected after nodulectomy |
| Secondary | Part 2 - Absence (or presence) of live female adult worms with normal embryogenesis | 24 months | Absence (or presence) of live female adult worms with normal embryogenesis assessed by histological examination of nodules collected after nodulectomy. |
| Secondary | Part 2 - Absence (or presence) of live female adult worms | 24 months | Absence (or presence) of live female adult worms, assessed by histological examination of nodules collected after nodulectomy |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05180461
GET https://conductscience.org/api/trials/v1/NCT05180461/registered